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Cancer is responsible for millions of deaths worldwide and the variability in disease patterns calls for
patient-specific treatment. Therefore, personalized treatment is expected to become a daily routine in pro-
spective clinical tests. In addition to genetic mutation analysis, predictive chemosensitive assays using
patient's cells will be carried out as a decision making tool. However, prior to their widespread application
in clinics, several challenges linked to the establishment of such assays need to be addressed. To best pre-
dict the drug response in a patient, the cellular environment needs to resemble that of the tumor. Further-
more, the formation of homogeneous replicates from a scarce amount of patient's cells is essential to
compare the responses under various conditions (compound and concentration). Here, we present a
microfluidic device for homogeneous spheroid formation in eight replicates in a perfused microenviron-
ment. Spheroid replicates from either a cell line or primary cells from adenocarcinoma patients were suc-
cessfully created. To further mimic the tumor microenvironment, spheroid co-culture of primary lung can-
cer epithelial cells and primary pericytes were tested. A higher chemoresistance in primary co-culture
spheroids compared to primary monoculture spheroids was found when both were constantly perfused
with cisplatin. This result is thought to be due to the barrier created by the pericytes around the tumor
spheroids. Thus, this device can be used for additional chemosensitivity assays (e.g. sequential treatment)
of patient material to further approach the personalized oncology field.1. Introduction
Despite huge efforts by researchers and pharmaceutical com-
panies to find new treatments, cancer remains one of the
leading causes of death worldwide. With 1.59 million deaths
in 2012,1 lung cancer-related fatalities represent the highest
fraction of mortalities in the world among the different can-
cer types. To reduce this number, a paradigm shift towards a
tailored treatment for each patient is emerging.2 Although
personalized genomic mutation assays are already performed
in clinics to identify specific types of cancers and their corre-
sponding targeted therapies, tumor recurrence and highvariability in disease patterns remain an important problem.3
To circumvent these issues, one further envisages testing and
analysing the patient's own cells in order to better predict the
individual response to a specific therapy regimen.
One of the challenges associated with such assays is
related to the small amount of patient's material available for
testing. Typically, a few micrograms of material can be
obtained from biopsies performed using fine needles of
which 0.5 to 1 million cells are typically extracted.4 The first
fraction of these cells is reserved for histological and geno-
mic assessments, while the second, from which undesired
cells are removed, is available for further analysis. Consider-
ing the tumor inhomogeneity and the unavoidable loss of
cells during the enzymatic digestion procedure, the number
of relevant cells available to perform reliable assays is very
limited. Another challenge of personalized medicine is in the
lack of appropriate in vitro models that have the capability to
predict the chemotherapeutic response for each patient. Tra-
ditional in vitro models often fail in predicting the in vivo
efficacy of specific chemotherapeutic agents5 and are thus
starting to be replaced by spheroid models that better reflect
the in vivo behavior of cells in tumor tissues.5–7 Besides the
three-dimensional cellular assembly, the tumoroyal Society of Chemistry 2015
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View Article Onlinemicroenvironment consists of a complex combination of
extracellular matrix, stroma cells and interstitial fluids. This
complex composition of the tumor microenvironment influ-
ences the tumor cell phenotype via mechanical and bio-
chemical factors that ultimately contribute to tumor
growth.8,9 Microfluidics, which enables the accurate control
of cell culture conditions, can ideally reproduce specific
aspects of the tumor microenvironment, such as the continu-
ous transport of nutrients and oxygen as well as the removal
of cellular waste products.10,11 In addition, microfluidic sys-
tems, in which individual cells can easily and accurately be
manipulated,12 make them ideal to handle scarce patient
material and are thought to represent the platform of choice
for the next generation of in vitro cancer models.13,14
A further challenge in personalized medicine models,
besides the use of primary cells15 and the small amount of
patient's cells available, represents the reproducibility of
in vitro tumors. So far, several groups reported concerning
the formation of spheroids on chip using either gravity
traps16 or trapping systems based on the creation of small
vortexes17 or removable trapping barriers.18 However, the cre-
ation of homogeneous spheroid replicates from limited
patient material has not yet been addressed. Additionally, a
tumor has to be seen as a unique and complex organ that
interacts with its microenvironment.19 The tumor microenvi-
ronment not only supports the tumor in maintaining prolifer-
ation,20 but represents also a barrier for drug delivery.21
Drugs have to overcome several barriers before reaching the
tumor where they shall destroy the tumor cells. Barriers for
intravenously administered drugs are, for instance the blood
vessels, walls through which drugs have to extravasate, or the
tumor interstitial site containing extracellular matrix, cancer-
associated fibroblasts or pericytes.21 Thus, the tumor micro-
environment plays a critical role in tumor development as
well as drug administration. Therefore, co-culture systems
further strengthen the reliability of in vitro model as in vivo-
like systems. In addition, Amann and colleagues22 observed
more compact and round microtissue surfaces in co-cultures
than in monocultures, showing the importance of co-culture
models. Especially pericytes, which play an essential role in
the stabilization of microvessels,23 are interesting as they ini-
tially accumulate at the interface of tumor and host tissue.24
In this study, we present a microfluidic system that
enables the homogeneous distribution of cells and the forma-
tion of spheroids in eight microwells using very low number
of cells that corresponds to a fraction of those obtained from
a tumor biopsy. Cells from a malignant pleural mesothelioma
cell line as well as cells obtained from patients with non-
small cell lung adenocarcinoma (NSCLC) following lung
resection are tested on the chip in terms of distribution
homogeneity and spheroid formation. Further, the cell line is
used to test cell viability and proliferation on chip to assess
the culture conditions. In addition, a chemosensitivity assay
with cisplatin is carried out under perfusion using primary
human lung adenocarcinoma spheroids. Primary spheroids
are cultured either as monoculture with epithelial cellsThis journal is © The Royal Society of Chemistry 2015(EpCAM + CD73 + CD90−) only or as co-culture using epithe-
lial cells and pericytes (EpCAM − CD73 + CD90+) from
patient-derived primary lung adenocarcinoma.
2. Materials and methods
2.1. Design of the microfluidic device for spheroid formation
The preparation of samples from patient material starts with
the enzymatic digestion of tissues obtained from a biopsy or
a lung resection. This step is followed by the selection of the
cells of interest by fluorescence-activated cell sorting (FACS)
and the formation of spheroids using these cells. To mini-
mize the manipulation of the delicate spheroids, we chose to
load the suspended FACS-sorted cells directly on the chip,
where they aggregate and form spheroids.
The first design prerequisite of the microfluidic device is
to produce samples with equal number of cells to enable the
formation of homogeneous replicates. The second is to do so
with a small number of FACS-sorted cells obtained from the
available patient material. To address these requirements we
were inspired by the dichotomy of the in vivo microvascula-
ture that distribute red blood cells equally to ensure a homo-
geneous distribution at branch points. A symmetrical tree-
like microstructure is designed to distribute the suspended
cells evenly in the eight microwells, in which they are trapped
by gravity. Per channel, three branches are considered to cre-
ate a total of eight replicates (ESI† Fig. S1) that enable the
secretion of sufficient cytokines or proteases to be detected
in the supernatant.11
The dimensions of the microfluidic channels were defined
to the minimal lateral resolution of about 100 μm in width
that can be achieved by stereolithography, the technique cho-
sen to produce the microfluidic chip. The required lengths of
the daughter channels were determined so that the eight
microwells would fit within a diameter of 9 mm, which corre-
sponds to the diameter of a well in a 96-well plate (ESI† Fig.
S1A). This feature makes the system compatible with modern
wide-field high-content imaging systems as well as with stan-
dard microplate readers, which will be investigated in further
studies.
The trapping of the suspended cells is driven by gravity
using a hydrostatic pressure difference between the inlet
(loading reservoir) and the outlet (collecting reservoir) of the
chip. When the suspended cells are flowing through the 200
μm wide daughter channel 3 and reach the 0.5 mm in diame-
ter microwells, their speed decreases, allowing cell sedimen-
tation at the bottom of the microwells (Fig. 1A).
2.2. Fabrication of the microfluidic device
Soft replicas of polydimethylsiloxane (PDMS, Dow Corning)
were cast on an epoxy mold made of Accura Extreme, pro-
duced by stereolithography (Proform AG, Switzerland), using
standard rapid prototyping protocols.25 Access ports were
punched with a 2 mm dermal biopsy punch (Shoney Scien-
tific, India) into a PDMS cover plate. The PDMS cast and
cover plate were then cleaned with 100% isopropanol andLab Chip, 2015, 15, 3076–3085 | 3077
Fig. 1 A) Cell loading principle: cells are loaded in the system using hydrostatic pressure and are trapped in the microwells by gravity. B) Top-view
picture of two microfluidic channels filled with red and yellow food dyes. C) Image of the epoxy mold with rounded micropillars, representing the
negative of the final channels. Scale bar corresponds to 1200 μm.
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View Article Onlinedried before being exposed to oxygen plasma for 25 s at 650
mTorr (Harrick Plasma, USA) enabling covalent bonding of
the two PDMS parts. After bonding, the assembled micro-
fluidic platforms were post-baked overnight at 60 °C in order
to strengthen the sealing between the two PDMS parts25
(Fig. 1B). As the process of stereolithography does not allow
the production of smooth round-bottom microwells, different
processing steps were needed to make round-bottom micro-
pillars. The first PDMS replica was produced using the Accura
Extreme mold as cast and cured through baking at 60 °C for
2 hours. Then the PDMS replica was silanized with
1H,1H,2H,2H-perfluoro-octyl-trichlorosilane (Fluorochem,
Brunschwig AG) at 80 °C overnight before casting a second
PDMS mold out of the silanized PDMS cast. After a curing
step of 2 hours at 60 °C in the oven, a drop of PDMS was
added on every micropillar of the second PDMS mold by
using a needle tip to make round-bottom microwells (ESI†
Fig. S2). Then the mold was also cured and silanized. A third
PDMS mold was cast out of the silanized second PDMS mold,
and also cured and silanized. In the final step, the epoxy cast-
ing resin (Weidling C, Weicon) was used to fabricate the final
mold out of the third and the last PDMS cast. The mold was
cured for 24 h at 40 °C. Finally we checked under a digital
microscope (Dino-Lite, IDCP B.V., Netherlands) the formation
of the round-bottom microwells (Fig. 1C). After silanization
with perfluoro-octyl-trichlorosilane, the epoxy mold was used
to fabricate all PDMS casts for the cellular assays as
described above. All the experiments were performed using
the round-bottom microwells unless otherwise stated.2.3. Cell culture
The microfluidic chip was tested with a mesothelioma cell
line (H2052) and with epithelial adenocarcinoma primary
cells obtained from patients with lung adenocarcinoma
(BE063-T and BE069-T) and squamous carcinoma (BE067-T)
as well as primary pericytes from one patient (BE069-T). The
protocol for the use of human material for research purposes
was approved by the Ethics Committee of the Canton of Bern,3078 | Lab Chip, 2015, 15, 3076–3085CH, and all the patients provided written informed consent
for the usage of surgical specimens and materials removed
for research purposes. Cells were manipulated in a sterile
flow hood and incubated at 37 °C and 5% CO2 unless other-
wise stated. Cell culture experiments with the mesothelioma
cell line H2052 ĲATCC-CRL-5915, ATCC, France) were
performed according to a previously described protocol.11
Briefly, cells were maintained in RPMI1640 (Invitrogen)
medium containing 10% fetal bovine serum, FBS (Sigma)
and 1% of a mixture of penicillin and streptomycin ĲP/S,
Invitrogen). TrypLE™ Express (LubioScience, Invitrogen) was
used to harvest cells, which were then counted following
Trypan blue staining using a hemocytometer (bright-line
Neubauer improved). The appropriate amount of cells was
then seeded either on the chip for perfusion experiments or
in a 96-well U-bottom plate (BD Falcon) for static experiments
in RPMI1640 medium supplemented with 20 ng ml−1 human
epidermal growth factor, hEGF (Gibco, Invitrogen), 20 ng
ml−1 basic fibroblast growth factor, bFGF (Gibco, Invitrogen),
4 μg ml−1 human insulin (BioReagent, Sigma), 2% serum-free
supplement B27 (Gibco, Invitrogen) and 1% P/S.
Primary lung epithelial tumor cells (PLETCs) as well as
primary pericytes (PCs) were isolated from lung tumor speci-
mens as previously described.26 In brief, PLETCs were pro-
spectively isolated using fluorescence-activated cell sorting
(FACS) with an immunophenotypic profile of Lineage-EpCAM
+ CD73 + CD90−, and were seeded for expansion in a 6-well
dish coated with 0.2% gelatin and human collagen IV (Sigma)
in CnT-PA growth medium (CellnTec, Switzerland)
supplemented with 10 ng ml−1 insulin-like growth factor,
IGF-2 (Peprotech) and 10 ng ml−1 heregulin β, HerB
(Peprotech). PCs were prospectively isolated with an
immunophenotypic profile of Lineage-EpCAM − CD73 +
CD90+ and were seeded for expansion in tissue culture plates
coated with 0.2% gelatin and human collagen IV in lung
pericyte growth medium (L-PC) composed of α-MEM medium
(Sigma) supplemented with 20 ng ml−1 hEGF, 20 ng ml−1
bFGF, 4 μg ml−1 human insulin, 1% FBS and a 1% antibi-
otic–antimycotic solution (Invitrogen). Primary cells wereThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineused up to four passages. Following institutional review
board approval, the patient, whose lung resection was used
in this study, signed the surgical patient consent form of the
University Hospital Bern, Switzerland, including the consent
for the usage of surgical specimens and materials removed
for research purposes.
2.4. Primary pericytes staining
PCs were stained to distinguish them from PLETCs.
Depending on the experiment purpose, different stains were
used. For short time experiments, a CellTrace™ CFSE cell
proliferation kit (Molecular Probes, Life Technologies) was
used. Therefore, pericytes were suspended in 10 μM CFSE
solution, incubated for 15 minutes, re-suspended in fresh
pre-warmed L-PC medium and incubated for another 30
minutes. PCs were then suspended again in fresh L-PC
medium and seeded on the chip either mixed with PLETCs
or alone. For long time experiments either a CellMask™
orange plasma membrane stain (Molecular Probes, Life Tech-
nologies) or a PKH26 red fluorescent cell linker (Sigma) was
used. For the CellMask™ orange stain, PCs were suspended
in a 1 : 1000 dilution of the CellMask™ orange stain, incu-
bated for 10 minutes at room temperature (RT) with occa-
sional mixing and washed once with fresh L-PC medium
before use. When using the PKH26 dye, PCs were suspended
in 2 × 10−6 M PKH26, incubated for 5 minutes at RT with
periodic mixing and followed by adding an equal volume of
1% bovine serum albumin, BSA (Sigma) for 1 minute before
adding L-PC medium. Finally cells were washed once with
L-PC medium and once with phosphate-buffered saline, PBS
(Gibco, Invitrogen) before use.
2.5. Cell loading and spheroid formation
Prior to cell loading, the microchannels were sterilized with
ozone (CoolCLAVE personal sterilizer), rinsed with 70% etha-
nol and degassed in a vacuum pump (KNF Neuberger) before
rinsing with sterile deionized water. Then, synperonic F-108
(1% w/v, Fluka, Sigma) was flushed through the micro-
channels to avoid cell adhesion on the channel walls and
incubated for 4 hours. Finally, the chip was rinsed with
RPMI1640 medium containing EGF, bFGF, insulin, B27 and
P/S for H2052 cell seeding, CnT-PA supplemented with IGF-2
and HerB for PLETCs or a 2 : 1 mixture of CnT-PA and L-PC
media for co-culture cell seeding. A hydrostatic pressure dif-
ference, induced by a few millimeter high cell culture
medium column containing the suspended cells, was used
for cell loading on the chip from the loading reservoir. Dur-
ing cell seeding, fresh medium was regularly added in the
inlet and the waste medium was removed from the outlet to
maintain the hydrostatic pressure difference. During cell
seeding, one minute video sequences were taken at the three
branch points by using a digital camera (Moticam 1000,
VWR). Video sequences of the cell seeding were used to count
the number of cells passing through the right and the left
arm at each branch and to determine the homogeneity of theThis journal is © The Royal Society of Chemistry 2015cell distribution in the tree-like structure. After cell seeding,
the microfluidic channels were incubated for 48 hours to
allow spheroid formation (see video in the ESI†). The
medium was exchanged once a day to ensure sufficient nutri-
ent supply to the cells. Furthermore, each microwell was
imaged once per day to observe and quantify spheroid forma-
tion and size. The formation of selected spheroids on the
microfluidic chip was also observed in time-lapse mode (1
picture every 10 minutes for 48 h) using a microscope placed
in the incubator (JuLI Smart Fluorescent Cell Analyzer). Table
1 indicates the number of H2052 cells that were loaded on
the chip using hydrostatic pressure and the corresponding
number of cells in each microwell. After cell seeding, the
microfluidic channels were incubated for 11 days and each
microwell was imaged once a day to observe and quantify
spheroid formation and growth. The medium was exchanged
once a day to ensure nutrient supply to cells.
Cell seeding for primary co-culture spheroids (PLETCs/PCs
spheroids) was done either sequentially or simultaneously.
With regard to the sequential seeding, PCs were seeded 48
hours after the PLETCs. During the simultaneous seeding,
PLETCs and PCs were mixed in an appropriate ratio, which
was obtained by testing different PLETC to PC ratios (2 : 1, 3 :
1, 4 : 1, 5 : 1, 7 : 1, 10 : 1, and 20 : 1), and then seeded on the
chip.
2.6. Proliferation assay on chip
A CellTrace™ CFSE Cell Proliferation Kit (Molecular Probes,
Invitrogen) was used to observe cell proliferation during
spheroid formation on the chip using dye dilution. Therefore
5 mM CFSE stock solution was diluted with phosphate-
buffered saline (PBS, Gibco, Invitrogen) to obtain a 10 μM
working concentration. The dye was added to only 1–2% of
the cell suspension so that stained cells could easily be dis-
tinguished and counted. Cells within the dye solution were
then incubated for 15 minutes before being centrifuged for 4
minutes at 200 relative centrifugal force (rcf). Then, the cells
were resuspended in fresh pre-warmed medium (RPMI1640)
and incubated for another 30 minutes to ensure complete
modification of the probe. Finally the cells were washed
again with the fresh medium and mixed with the non-stained
cells before seeding all cells on the chip. Microscopic pictures
were taken once a day using an inverted fluorescence micro-
scope (Leica DMI4000B). In addition, proliferation during
spheroid formation was observed by time-lapse microscopy
every hour using the JuLI analyzer.
2.7. Perfusion and cisplatin treatment on chip
For chemosensitive assays, 5000 cells per channel were
seeded and incubated for 48 hours to enable spheroid forma-
tion. The ratio between PLETCs and PCs was set to 5 : 1,
meaning 4167 PLETCs and 833 PCs were mixed and seeded
per channel. The medium was exchanged once a day to
ensure sufficient nutrient supply. After spheroid formation,
the inlet channels of the microfluidic chips were connectedLab Chip, 2015, 15, 3076–3085 | 3079
Table 1 Summary of the experiment showing the amount of H2052 cells seeded per channel and the corresponding theoretical values per microwell
as well as the measured spheroid diameters after 3 and 11 days
Number of cells loaded on
chip
Theoretical number of cells
per well
Diameter of spheroids after 3 days on
chip (μm)
Diameter of spheroids after 11 days on
chip (μm)
10 000 1250 324 ± 36 357 ± 20
5000 625 262 ± 39 300 ± 41
2500 312 210 ± 20 250 ± 37
1250 156 186 ± 28 175 ± 38
Lab on a ChipPaper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
2 
Ju
ne
 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
9/
11
/2
01
5 
07
:1
5:
44
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineto syringe pumps (Harvard Apparatus) equipped with 1 ml
syringes. For this, polytetrafluoroethylene (PTFE, Milian)
tubes, which have an inner diameter (ID) of 0.8 mm, connect
the syringes with the inlet of the channels. Each of the tubes
is interrupted by an air bubble trap shortly before the chan-
nel inlet to avoid the entry of air bubbles into the micro-
fluidic channels. The air bubble trap consists of a polyvinyl
chloride (PVC) tubing (ID = 2 mm) enclosing a 1.6 mm PTFE
tube (ID = 0.8 mm), which collects the air bubbles. The outlet
channels of the chip were connected as well to the PTFE
tubes (ID = 0.8 mm) ending in 1.5 ml microtubes (Eppendorf,
VWR) that finally collect the supernatant during the whole
assay period. Spheroids were perfused for 48 hours under
sterile conditions at 37 °C and 5% CO2 with a flow rate of 0.1
μl min−1 and different concentrations of cisplatin (0 μM, 2
μM, 4 μM, 8 μM, 16 μM, 32 μM, 48 μM, 64 μM, 80 μM, 96
μM, 112 μM, 128 μM, and 144 μM). For this purpose, cis-
platin (0.5 mg ml−1, Sandoz) was diluted with the appropriate
medium. Consequently, RPMI1640 medium supplemented
with 20 ng ml−1 hEGF, 20 ng ml−1 bFGF, 4 μg ml−1 human
insulin, 2% B27 and 1% P/S was used for experiments with
the mesothelioma cell line H2052, whereas PLETCs were per-
fused with CnT-PA medium supplemented with 10 ng ml−1
IGF-2 and 10 ng ml−1 HerB and co-culture spheroids with a
combination of CnT-PA medium supplemented with 10 ng
ml−1 IGF-2 and 10 ng ml−1 HerB and L-PC medium in a 2 : 1
ratio. The final supernatant volume of 288 μl was then
analysed for its caspase-3/7 activity. All experiments were
done at least in triplicate.
2.8. Caspase-3/7 activity
After cisplatin treatment, supernatants were quickly frozen
down in liquid nitrogen and stored at −80 °C until they were
used to measure the caspase-3/7 activity. For this purpose,
the supernatants were rapidly thawed in a 37 °C water bath.
Then, 100 μl of each supernatant was mixed in a 1 : 1 ratio
with the Caspase-Glo®3/7 assay (Promega) in a black 96-well
flat-bottom plate and incubated for 60 minutes before lumi-
nescence was measured using a plate reader (TECAN Infinite
M1000).
2.9. Cell viability staining on chip
A live/dead stain was performed by using calcein and
ethidium homodimer 1 (EthD1, Viability Cytotoxicity Kit,
Invitrogen). In addition, Hoechst 33342 (Molecular Probes,3080 | Lab Chip, 2015, 15, 3076–3085Invitrogen) was used to stain the cell nuclei. For this, 0.5 μM
calcein was mixed with 1 μM EthD1 and 1 μg ml−1 Hoechst
33342 in RPMI1640 medium containing EGF, bFGF, insulin,
B27 and P/S. The combined reagents were added to the
spheroids and incubated for 3 hours. Following this, the
spheroids were washed with RPMI1640 medium containing
EGF, bFGF, insulin, B27 and P/S and observed under the
fluorescence microscope.
2.10. Microscopy and image analysis
Microscopic pictures were taken using an inverted Leica fluo-
rescence microscope (Leica DMI4000B) with a CCD camera
(Leica DFC360 FX) or with a laser scanning microscope (Zeiss
LSM710) for fluorescence-labelled cells. The JuLI analyzer
was used for time serial images for longer duration and the
digital Moticam camera was used to take daily bright-field
images as well as video sequences. The images were
processed using the Leica AF image analysis software and
were further treated and visually analyzed using the Fiji
image analysis software based on ImageJ (http://rsbweb.nih.
gov/ij/).
2.11. Statistical analysis
Prism6 (GraphPad Software, Inc., La Jolla, CA) was used for
statistical analysis. The statistical significance was set at a
value of 0.05.
3. Results and discussion
3.1. Cell loading and distribution in the microfluidic branch
In contrast to other microfluidic systems aimed at creating
spheroids on chip,16,27–29 the aim of the present system is to
load a defined number of cells on the chip to form spheroids
with a minimum cell loss. A known amount of cells (MPM
H2052 have an approximate size of 20 μm) is pipetted at the
inlet of the channel and transported by hydrostatic pressure
in the microfluidic network. At the first branch, the cells are
distributed equally in the two daughter branches. 51.8 ±
4.5% of the cells are transported in the left branch, while
48.2 ± 4.5% in the right branch (ESI† Fig. S3). At the second
branch, the cells split equally again (51.4 ± 3.9% (left branch)
and 48.6 ± 3.9% (right branch)), as well as at the last intersec-
tion, 52.8 ± 7.2% are counted in the left and 47.2 ± 7.2% in
the right branch. The standard errors are within a few per-
centages and are thus acceptable. The distribution of theThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinecells as a function of the position of the microwells in the
microvasculature is homogeneous with a slightly higher num-
ber of cells in the first and last wells. This difference is how-
ever not significant in comparison with the number of cells
trapped in the other microwells (ESI† Fig. S4). Overall, a
homogeneous distribution of the cells is obtained with this
device even when a very low number of cells are seeded.
Almost all loaded cells are trapped in the microwells, with no
remaining cells observed either in the inlet of the device, or
after the trapping section. Indeed, about 150 cells are found
in each microwell for the smallest cell density loaded. These
results demonstrate that the efficiency of the device in terms
of cell loss is excellent.3.2. Spheroid formation with the H2052 cell line
During the first three days after seeding, the diameters of the
cellular aggregates significantly decrease regardless of the
number of cells seeded (Fig. 2). During this time, the cell–cell
contacts become stronger and tight junctions are created,
which results in a compact cellular structure (Fig. 2B). After
this initial formation phase of the spheroids, the spheroid
diameters start to increase as a consequence of cellular pro-
liferation. This tendency is observed until the end of the cul-
ture at day 11 after cell seeding. Between day 3 and day 11 in
the culture, the diameters of the spheroids increase by 19%
in the channels seeded with 2500 cells, and by 14% in the
channels seeded with 5000 cells and by 10% in the channels
seeded with 10 000 cells (Fig. 2A). This increase in spheroid
size is statistically significant for 2500 cells seeded between
day 3 and day 10 as well as for 5000 cells seeded between day
3 and days 9, 10 and 11. The smaller spheroids formed with
only 156 cells changed minimally over time. The lowest diam-
eter is reached merely after 7 days and increases by only 2%
until day 11 in the culture. A minimal amount of cells seems
to be needed to favor cellular proliferation. In the present
case, the critical limit is situated between 150 to 250 MPMThis journal is © The Royal Society of Chemistry 2015
Fig. 2 A) Graph showing the cellular aggregate diameter over a period
presented as mean ± SEM. Statistical significance was calculated compared
tion on chip with round-bottom microwells. The images were taken 24, 48
N ≥ 8.H2052 cells. This may be due to insufficient production of
extracellular matrix from the cells. Similar results were
observed in a standard 96-well plate (results not shown),
which suggests that this limit is not due to the microfluidic
confinement.3.3. Difference between flat-bottom and round-bottom wells
Stereolithography, the technique used to create the PDMS
mold, does not enable the creation of smooth spherical
micropillars to be used for the molding of round-bottom
microwells, due to its resolution limits. Rounded micropillars
are thus produced by manually adding uncured PDMS drop-
lets on the stereolithographic mold. This process appears to
be reproducible (Fig. 1C). For 10 000 cells loaded per channel,
an important difference in the number of spheroids formed
in each microwell is observed between flat-bottom and
round-bottom microwells (Fig. 3A and B). In the flat-bottom
microwells, after 24 hours in culture, only 14% of the wells
contains a single spheroid, whereas 23.4% contains two
spheroids, 35.9% contains three spheroids and 26.6% of the
microwells even with four spheroids (Fig. 3A). In sharp con-
trast, 75% of the round-bottom receptacles contain only one
spheroid after one day in culture. In addition, the presence
of multiple spheroids was only observed in 20.3% of the
round-bottom microwells (two spheroids) and in 3.2% of the
microwells (three or four spheroids) (Fig. 3B). We observe
that the number of spheroids per cavity decreases with time.
After 3 days in culture, a single spheroid is formed in 42.2%
of the flat-bottom microwells, and in 78.1% of the round-
bottom microwells, respectively (Fig. 3C). Our results demon-
strate the importance of the microwell shape and of the cell
culture time to obtain similar replicates. Fig. 3D shows repre-
sentative images of round and flat-bottom wells. As a result,
all subsequent tests are carried out with the round-bottom
microwells.Lab Chip, 2015, 15, 3076–3085 | 3081
of 11 days as a function of the number of cells seeded. The data are
to day 3 after seeding. N ≥ 8. B) Bright-field images of spheroid forma-
, 72 and 96 hours after cell seeding. Scale bar corresponds to 250 μm.
Fig. 3 Experiments with MPM H2052 cell line. Percentage of microwells containing either one spheroid (dark), two spheroids (dark grey),
three spheroids (grey) or four spheroids (light grey) in flat-bottom microwells A) or round-bottom microwells B). C) Comparison between percent-
age of microwells with a flat or round-bottom microwells containing one spheroid. D) Representative images of spheroids formed in flat-bottom
microwells and round-bottom microwells after three days in culture. Scale bar corresponds to 250 μm. For all experiments N = 64. E) Images
showing spheroids stained with Hoechst (blue) and Ethidium homodimer-1 (EthD1, red) indicating cell death. Scale bar corresponds to 500 μm. F)
Graph representing cell mortality in spheroids after 2 days (N = 16), 8 days (N = 16) and 10 days (N = 8) on chip. The data are represented as
mean ± SEM.
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View Article Online3.4. Cell proliferation and viability in the H2052 cell line
Cell viability and proliferation in the spheroids were investi-
gated for a period of at least 8 days (Fig. 3E and F). Cell death
was assessed by the loss of plasma membrane integrity using
ethidium homodimer-1 and found to be 10.5 ± 3% after 2
days. Cell mortality remains stable over a period of 8 days
with a cell mortality of 10.5 ± 2.9%. These results fit with our
previous findings where a cell mortality of 10% was found.11
After 10 days on the chip, cell mortality increases slightly to
16.9 ± 4.9% (Fig. 3F). This can be explained by the formation
of a necrotic core typical to spheroids that are larger than3082 | Lab Chip, 2015, 15, 3076–3085300 μm.7 Cell proliferation was assessed on spheroids with
only 150 cells, which enables the imaging of cell division
within the spheroids. CFSE covalently binds to intracellular
molecules and therefore the fluorescent CFSE can be retained
within the cell for a long time. In our case, CFSE was used to
track cell proliferation within the chip over a period of 8 days
(ESI† Fig. S5). We chose to stain only few cells with CFSE to
ease the observation of proliferation in the spheroids. Cells
proliferate slower in 3D cultures compared to a standard
monolayer cell culture, as reported earlier by our group using
MPM cells11 and by additional groups using other cells.30–34This journal is © The Royal Society of Chemistry 2015
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View Article Online3.5. Human lung primary cell spheroids: mono- and
co-culture
As the ultimate aim of this platform is to perform personal-
ized chemosensitivity assay, primary tumor cells from
patients with NSCLC are loaded on the chip. 10 000 PLETCs
obtained from lung tumor resection of one adenocarcinoma
patient (BE063-T) and one squamous carcinoma patient
(BE067-T) were loaded and cultured in the round-bottom
microwell platform. Cellular distribution in the eight micro-
wells was homogeneous, which resulted in spheroid diame-
ters with a standard error of 4.6 μm after three days. Surpris-
ingly, in contrast to the 75% of single MPM H2052 spheroids
obtained per well, about 90% of the microwells contain a sin-
gle spheroid after 24 hours (Fig. 4A). In addition, no wells
contain more than two spheroids. Thus, intercellular adhe-
sion and formation of the cellular aggregates may increase
with primary cells. The percentage of wells containing only
one spheroid remains stable over a period of three days
(Fig. 4A). The diameter of the cellular aggregates decreases
from 220 ± 45 μm after 24 hours on the chip to 176 ± 35 μm
after three days (Fig. 4B), which corresponds to the formation
of a compact spheroid. The cells from both patients formedThis journal is © The Royal Society of Chemistry 2015
Fig. 4 Experiments with primary lung tumor cells. Experiments in A) an
(adenocarcinoma) and BE067-T (squamous carcinoma)), whereas experimen
of microwells containing one or two spheroids. B) Diameter of primary cells
taken daily during 3 days of mono- or co-culture spheroids cultured on ch
250 μm.uniformly sized spheroids. In total, 32 wells were observed
and analyzed per patient. However, a difference was observed
between spheroids from the two patients. When using the
cells from patient BE063, a primary adenocarcinoma, the
number of wells containing more than one spheroid
increases from 2 wells in the first day to 5 wells after three
days. In contrast, the number of wells containing multiple
spheroids decreases with the cells from patient BE067, a pri-
mary squamous carcinoma, from 1 well at day one to 0 wells
after three days.
The complexity of the tumor microenvironment imposes
several barriers that limit drug diffusion to the cancerous
cells. Extracellular matrix, smooth muscle cells, pericytes,
cancer-associated fibroblasts and others are creating a protec-
tive barrier from the drug around the tumor.21 In an attempt
to further reproduce a part of this barrier, primary pericytes
(PCs) are co-cultured with primary lung adenocarcinoma epi-
thelial cells (PLETCs). PCs as well as PLETCs that are tested
on the chip were collected from the same patient (BE069-T).
Co-seeding and sequential seeding strategies are tested to
create co-cultured spheroids. As sequential seeding often
results in the formation of two distinct spheroids, one with
PCs and the second with PLETCs (data not shown), theLab Chip, 2015, 15, 3076–3085 | 3083
d B) were performed with primary cells from two patients (BE063-T
ts in C) were done with patient BE069-T (adenocarcinoma). A) Number
spheroids. The data are presented as mean ± SEM. (N ≥ 59). C) Images
ip. Pericytes were stained in red with PKH26. Scale bar corresponds to
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View Article Onlinedecision was taken to continue with the co-seeding strategy,
where homogeneous spheroids formed after 24 hours. The
optimal ratio between PLETCs and PCs was found to be 5 : 1.
At lower ratios no spheroid formation was observed, but
instead an accumulation of loose cells. At higher ratios,
homogeneous spheroids formed (ESI† Fig. S6).
Fluorescence microscopy images strikingly illustrate the
difference in the spheroids obtained from the monoculture
or from the co-culture of primary cells. The co-culture spher-
oids are covered with pericytes, which seem to constrain the
spheroid diameter, whereas the spheroids without pericytes
are slightly larger (Fig. 4C). However, no difference was
observed in terms of spheroid formation between monocul-
ture and co-culture spheroids.3.6. Cisplatin assay
Cisplatin, a platinum-containing anti-cancer drug that causes
crosslinking of DNA and thus triggers apoptosis, is com-
monly used to treat patients with lung adenocarcinoma. The
same drug is used here. In our earlier work we presented a
difference in chemosensitivity of cisplatin under static and
perfusion conditions in H2052 cells.11 The quantification of
the chemoresistance was performed by analyzing the per-
fused supernatant collected after 48 hours of cisplatin expo-
sure. In the present study, the objective is to investigate the
chemoresistive effect of the pericytes co-cultured with lung
cancer epithelial cells. For this purpose, PLETCs and PLETC/
PC spheroids with similar number of cells, estimated at
about 600, were perfused with different concentrations of cis-
platin (Fig. 5). Interestingly, PLETC/PC spheroids in our per-
fused system show a maximum number of apoptotic cells at
a cisplatin concentration of 80 μM, whereas in monoculture
spheroids the maximum is already reached at 16 μM of3084 | Lab Chip, 2015, 15, 3076–3085
Fig. 5 Graph showing the response to cisplatin of primary mono and
co-culture spheroids of one patient under perfusion. A maximum of
apoptotic cells was measured at 16 mM for monoculture spheroids
and at 80 mM for co-culture spheroids on chip. The data are
presented as mean ± SEM and were normalized to control. N ≥ 3,
except for 2 mM cisplatin where only 2 samples were tested.cisplatin. The decrease in apoptotic signal after this apopto-
sis peak is explained by the induction of necrotic cell death,
which is not measured by the caspase-3/7 assay, due to cis-
platin toxicity. Hence in our microfluidic chip PLETC spher-
oids are more sensitive to cisplatin than the PLETC/PC spher-
oids under perfusion. Thus, primary pericytes seem to play a
protective role for primary lung cancer epithelial cells.
4. Conclusions
Microfluidic devices aimed for personalized chemotherapy
are widely seen as having the potential to become important
tools for the prediction of a patient's response to chemother-
apeutic treatment.13 The scarce material obtained from
patient's tumors need to be used carefully and as efficiently
as possible to extract the maximum amount of information
(genomic, proteomic, histology and cell-based assays). Thus,
physicians are assisted in the decision-making process aimed
at determining the most appropriate chemotherapy. Given
that the number of available cells is very limited for a cell-
based assay, one of the important parameters of a micro-
fluidic platform for personalized chemotherapy is to provide
reliable results despite this constraint. Thus, homogeneous
spheroid formation from patient's material in an in vivo-like
environment is necessary to obtain reliable results. Therefore,
the first objective of this study was to design a microfluidic
device that enables the homogeneous distribution of a given
number of cells leading to reproducible spheroid formation
across test samples. In the second step, the drug response of
primary cells in a perfused microenvironment was tested.
This study demonstrates the first step in the direction of
personalized oncology application with the formation of
spheroids of equal sizes from a very limited number of cells
and drug perfusion on human primary cells. This micro-
fluidic device is able to form single, uniformly sized spher-
oids from either cell line or human primary cells. As little as
1250 cells per channel, translating into around 156 cells per
spheroid, were loaded on the platform and formed spheroids.
Importantly, the system's efficiency is high with almost no
cell loss in the microfluidic network. Further, the cell viability
and proliferation of the confined spheroids was revealed to
be robust, which was demonstrated by the constant cell via-
bility over 8 days. Moreover the optimal ratio between the pri-
mary epithelial lung tumor cells (PLETCs) and the primary
pericytes (PCs) in the presented microfluidic system was
found to be 5 : 1. The most important finding is that pericytes
have a protective effect on the lung cancer epithelial cells
from the damaging effects of a chemotherapeutical drug,
leading to a higher chemoresistance of PLETC/PC spheroids
compared to the PLETC spheroids.
These results demonstrate that we could reproduce at
least partly the barrier induced by the tumor microenviron-
ment that protects the tumor from drug exposure. To mimic
this microenvironment even further, other constituents of
the tumor, such as the endothelial microvasculature, are
needed. Microfluidic systems like this one will also allowThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinereproduction of combined or sequential chemotherapies that
are often used in clinics. These developments will bring such
microfluidic chips closer to being a potential tool to be used
in personalized oncology.
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